Literature DB >> 21191114

How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.

Charlie Schmidt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21191114     DOI： 10.1093/jnci/djq557

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  9 in total

Review 1.  Molecular-targeted nanotherapies in cancer: enabling treatment specificity.

Authors:  Elvin Blanco; Angela Hsiao; Guillermo U Ruiz-Esparza; Matthew G Landry; Funda Meric-Bernstam; Mauro Ferrari
Journal:  Mol Oncol       Date:  2011-10-25       Impact factor: 6.603

2.  Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.

Authors:  Edith A Perez; Amylou C Dueck; Ann E McCullough; Monica M Reinholz; Kathleen S Tenner; Nancy E Davidson; Julie Gralow; Lyndsay N Harris; Leila A Kutteh; David W Hillman; Robert B Jenkins; Beiyun Chen
Journal:  J Natl Cancer Inst       Date:  2011-12-02       Impact factor: 13.506

3.  On Enrichment Strategies for Biomarker Stratified Clinical Trials.

Authors:  Xiaofei Wang; Jingzhu Zhou; Ting Wang; Stephen L George
Journal:  J Biopharm Stat       Date:  2017-10-30       Impact factor: 1.051

4.  Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping.

Authors:  Julia D Wulfkuhle; Daniela Berg; Claudia Wolff; Rupert Langer; Kai Tran; Julie Illi; Virginia Espina; Mariaelena Pierobon; Jianghong Deng; Angela DeMichele; Axel Walch; Holger Bronger; Ingrid Becker; Christine Waldhör; Heinz Höfler; Laura Esserman; Lance A Liotta; Karl-Friedrich Becker; Emanuel F Petricoin
Journal:  Clin Cancer Res       Date:  2012-10-08       Impact factor: 12.531

5.  Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.

Authors:  Julian C Schink; Julia R Trosman; Christine B Weldon; Kalliopi P Siziopikou; Gregory J Tsongalis; Alfred W Rademaker; Jyoti D Patel; Al B Benson; Edith A Perez; William J Gradishar
Journal:  J Natl Cancer Inst       Date:  2014-09-12       Impact factor: 13.506

6.  High-density SNP arrays improve detection of HER2 amplification and polyploidy in breast tumors.

Authors:  Thomas V O Hansen; Jonas Vikesaa; Sine S Buhl; Henrik H Rossing; Vera Timmermans-Wielenga; Finn C Nielsen
Journal:  BMC Cancer       Date:  2015-02-06       Impact factor: 4.430

7.  HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.

Authors:  Albina Stocker; Marie-Luise Hilbers; Claire Gauthier; Josias Grogg; Gerd A Kullak-Ublick; Burkhardt Seifert; Zsuzsanna Varga; Andreas Trojan
Journal:  PLoS One       Date:  2016-07-27       Impact factor: 3.240

8.  Why clinical translation cannot succeed without failure.

Authors:  Alex John London; Jonathan Kimmelman
Journal:  Elife       Date:  2015-11-24       Impact factor: 8.140

9.  Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing.

Authors:  Alexandre Vivot; Isabelle Boutron; Geoffroy Béraud-Chaulet; Jean-David Zeitoun; Philippe Ravaud; Raphaël Porcher
Journal:  Sci Rep       Date:  2017-07-31       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.